xRead - September 2022

Wise et al.

Page 317

Author Manuscript Author Manuscript Author Manuscript Author Manuscript TABLE VII.A.2-1.

Effect of allergic rhinitis on sleep in adults Study Year LOE Study design Study groups Clinical endpoint Conclusion Shanqun et al. 709 2009 1b RCT AR and OSA (n = 89): 1 Montelukast + budesonide (n = 44); 2 Placebo (n = 45) ESS, RQLQ, TSS, CSAQLI, symptoms diary

Montelukast + budesonide improves AR and OSA QOL, sleep quality, and daytime somnolence. Mansfield & Posey 708 2007 1b RCT 1 Fluticasone (n = 16); 2 Placebo (n = 16)

TOVA, ESS, TSS Fluticasone improves daytime sleepiness, cognitive performance, and nasal symptoms. Gurevich et al. 705 2005 1b RCT, crossover PAR (n = 26), nasal budesonide ESS, sleep diary, questionnaire

Budesonide reduces nasal congestion, daytime somnolence/fatigue, and improves sleep quality in PAR. Hughes et al. 706 2003 1b RCT, crossover PAR (n = 22), nasal budesonide vs placebo ESS, FOSQ, RQLQ, symptom diary Budesonide improves daytime fatigue and sleep quality in PAR. Craig et al. 707 1998 1b RCT, crossover AR (n = 20), flunisolide vs placebo Symptom and sleep diary Nasal corticosteroids improve symptoms and subjective sleep compared to controls. Parikh et al. 715 2014 2b Observational cohort OSA and rhinitis (n = 43) ESS, symptoms scores, CPAP compliance cohort

Control of rhinitis (with varying regimens of steroid sprays, antihistamines, leukotrienes

inhibitors, anticholinergics, etc.) important for OSA control. No difference: AR vs NAR.

OSA and AR (n = 80) ESS, PSG Nasal corticosteroids improve sleep quality and AR symptoms. Addition of antihistamine did not have effect. 1 OSA and AR (n = 34); 2 OSA without rhinitis (n = 21) Daytime workers (n = 3442) Questionnaire, ESS, SF-36

PSG, nasal biopsies In AR, nasal corticosteroids reduce nasal inflammation and improve PSG parameters.

Severity of nasal obstruction (nonvalidated questionnaire) correlates with worse ESS and lower QOL. rhinitis QOL and sleep quality.

Mintz et al. 724 2004 2b Individual cohort AR (n = 651) Nocturnal RQLQ, PSQI Treatment with triamcinolone improves nocturnal Camhi et al. 713 2000 2b Case-control n = 437 from TESOAD with sleep problems/ snoring Janson et al. 725 1996 2b Observational cross-sectional n = 2661 random population of the ECRHS SPT, methacholine challenge, questionnaire AR independently associated with difficulty initiating sleep and daytime sleepiness (OR 2.0). Colas et al. 726 2012 2c Population-based AR (n = 2275) TSS, RQLQ, PSQI AR disease severity has strong relationship with sleep disturbance. Questionnaire AR is a risk factor for snoring.

cross-sectional

cross-sectional

Acar et al. 716 2013 2b Observational

Lavigne et al. 717 2013 2b Observational

Udaka et al. 723 2007 2b Observational

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.